Lois Chandler - Taxus Cardium Chief Officer
| CRXMDelisted Stock | USD 0.0001 0.00 0.00% |
Insider
Lois Chandler is Chief Officer of Taxus Cardium Pharmaceuticals
| Age | 65 |
| Phone | 858 414 1477 |
| Web | https://genebiotherapeutics.com |
Taxus Cardium Management Efficiency
The company has return on total asset (ROA) of (2.619) % which means that it has lost $2.619 on every $100 spent on assets. This is way below average. Taxus Cardium's management efficiency ratios could be used to measure how well Taxus Cardium manages its routine affairs as well as how well it operates its assets and liabilities.Taxus Cardium Pharmaceuticals currently holds 1.26 M in liabilities. Taxus Cardium Pharma has a current ratio of 0.08, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Taxus Cardium until it has trouble settling it off, either with new capital or with free cash flow. So, Taxus Cardium's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Taxus Cardium Pharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Taxus to invest in growth at high rates of return. When we think about Taxus Cardium's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Jack Anders | Revolution Medicines | 48 | |
| Owen Wallace | Monte Rosa Therapeutics | 55 | |
| Mercedes Carrasco | Akebia Ther | N/A | |
| John Castle | Monte Rosa Therapeutics | 53 | |
| Sharon Townson | Monte Rosa Therapeutics | 49 | |
| Filip MD | Monte Rosa Therapeutics | 50 | |
| Tanya MS | Replimune Group | 53 | |
| Tracey Esq | Blueprint Medicines Corp | 56 | |
| Steven MD | Cabaletta Bio | 63 | |
| FACR MD | Cabaletta Bio | 59 | |
| Violetta Cotreau | Akebia Ther | 51 | |
| Jennifer Champoux | Monte Rosa Therapeutics | N/A | |
| Michael Todisco | Kymera Therapeutics | 59 | |
| Heather MSc | Cabaletta Bio | N/A | |
| Bruce CFA | Kymera Therapeutics | N/A | |
| Ajim CFA | Monte Rosa Therapeutics | 47 | |
| Chandra Lovejoy | Erasca Inc | 53 | |
| DPhil DPHIL | Kymera Therapeutics | 48 | |
| CPA MS | Erasca Inc | 55 | |
| David Spellman | Akebia Ther | 47 | |
| Phil JD | Monte Rosa Therapeutics | 45 | |
Management Performance
| Return On Asset | -2.62 |
Taxus Cardium Pharma Leadership Team
Elected by the shareholders, the Taxus Cardium's board of directors comprises two types of representatives: Taxus Cardium inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Taxus. The board's role is to monitor Taxus Cardium's management team and ensure that shareholders' interests are well served. Taxus Cardium's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Taxus Cardium's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ronald Shebuski, Chief Officer | ||
| Christopher Reinhard, Co-Founder, CEO and President Treasurer and Executive Director | ||
| Lois Chandler, Chief Officer | ||
| Duane Linstrom, G Counsel | ||
| James Grainer, CFO Chairman | ||
| Kelly Scott, VP Inc |
Taxus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Taxus Cardium a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -2.62 | |||
| Current Valuation | 881.11 K | |||
| Shares Outstanding | 64.93 M | |||
| Shares Owned By Insiders | 0.21 % | |||
| Number Of Shares Shorted | 150.25 K | |||
| Price To Book | 3.36 X | |||
| Price To Sales | 137.13 X | |||
| EBITDA | (458.68 K) | |||
| Net Income | (517.9 K) | |||
| Cash And Equivalents | 386.03 K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Other Consideration for investing in Taxus Pink Sheet
If you are still planning to invest in Taxus Cardium Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Taxus Cardium's history and understand the potential risks before investing.
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |